mTOR Pathway Substrates Present High Activation in Vascular Malformations and Significantly Decrease with AgeArticle Published on 2023-12-252024-09-05 Journal: Diagnostics [Category] update2024, [키워드] lymphatic malformation mTOR Rapamycin Sirolimus Vascular anomalies venus malformation [DOI] 10.3390/diagnostics14010038 PMC 바로가기 [Article Type] Article
Blazing a trail for the clinical use of rapamycin as a geroprotecTOROriginal Article Published on 2023-10-062024-09-05 Journal: GeroScience [Category] update2024, [키워드] aging Everolimus metabolism mTOR muscle Sirolimus [DOI] 10.1007/s11357-023-00935-x PMC 바로가기 [Article Type] Original Article
Evaluation of off-label rapamycin use to promote healthspan in 333 adultsArticle Published on 2023-05-162024-09-05 Journal: GeroScience [Category] update2024, [키워드] aging COVID-19 healthspan Longevity Rapamune SARS-CoV-2 Side effects Sirolimus [DOI] 10.1007/s11357-023-00818-1 PMC 바로가기 [Article Type] Article
Translation suppression underlies the restrained COVID-19 mRNA vaccine response in the high-risk immunocompromised groupArticle Published on 2022-10-262023-07-10 Journal: Frontiers in Immunology [Category] COVID19(2023년), [키워드] COVID-19 mRNA vaccines Immunocompromised patients mycophenolate Sirolimus tacrolimus translation suppression. [DOI] 10.3389/fimmu.2022.1020165 PMC 바로가기
Rapamycin and inulin for booster vaccine response stimulation (RIVASTIM)-rapamycin: study protocol for a randomised, controlled trial of immunosuppression modification with rapamycin to improve SARS-CoV-2 vaccine response in kidney transplant recipientsArticle Published on 2022-09-152022-11-15 Journal: Trials [Category] SARS, 진단, [키워드] 1:1 binding domain Booster vaccine cell-mediated response clinical Controlled trial COVID COVID-19 COVID-19 vaccination COVID-19 vaccine death develop disease severity dose Effectiveness Efficacy ENhance hospitalisation humoral hypothesise IgG immune cell population immunological Immunosuppression IMPROVE include increased risk Intervention kidney transplant recipient kidney transplant recipients Kidney transplantation live SARS-CoV-2 Modification mTOR inhibitor multicentre neutralisation New outcome participant Prednisolone Primary outcome proportion Protective protective immunity public health randomised randomised controlled trial Rapamycin recipient reduce reduced regimen registry responses SARS-CoV-2 SARS-CoV-2 vaccine secondary serological Sirolimus Standard of care Study protocol Tolerability Trial vaccination Vaccine vaccine response virus [DOI] 10.1186/s13063-022-06634-w PMC 바로가기
Can We Use mTOR Inhibitors for COVID-19 Therapy?Article Published on 2022-01-012023-06-23 Journal: Combinatorial chemistry & high throughput screening [Category] 신종인플루엔자, [키워드] COVID-19 Everolimus mTOR inhibitors Rapamycin SARS-CoV-2 Sirolimus temsirolimus. [DOI] 10.2174/1386207325666211130140923
Therapeutic mTOR blockade in systemic autoimmunity: Implications for antiviral immunity and extension of lifespan전신 자가면역에서 치료적 mTOR 차단: 항바이러스 면역 및 수명 연장에 대한 시사점Review Published on 2021-12-012022-09-11 Journal: Autoimmunity reviews [Category] SARS, 치료제, [키워드] Activation adaptive Adaptive immune response aging Antigen antigen-presenting cell antiviral immunity APC Autoimmunity blockade Cell cell fate characterized clinical Clinical effect clinical trials cognate antigen conserved contraction COVID-19 infection Critical cytokine Cytokines disease Efficacy Engagement ENhance evaluate Evidence expansion extension form Health healthy highlight Immune cell lineage specification in viral Infection Inflammation Influenza Influenza virus innate immune system Lifespan extension Lineage lupus erythematosus Mechanistic target of rapamycin mTOR pathway Plasma cell Plasma cells preliminary evidence pro-inflammatory Protective protective immunity protein complex provide provided Rapamycin receptor reduce regulatory T cells responsiveness shown Sirolimus SLE SLE patient SLE patients subjects systemic systemic lupus erythematosus T cell T cell activation T cell receptor T cells TCR Th17 Treatment Trial vaccination viral infection viral infections [DOI] 10.1016/j.autrev.2021.102984 PMC 바로가기 [Article Type] Review
Drug repurposing for coronavirus (SARS-CoV-2) based on gene co-expression network analysis유전자 공동 발현 네트워크 분석에 기초한 코로나 바이러스 (SARS-COV-2)에 대한 약물 재생Article Published on 2021-11-082022-08-31 Journal: Scientific Reports [Category] MERS, SARS, 바이오마커, 신약개발, 유전자 메커니즘, 치료기술, 치료제, [키워드] acute respiratory syndrome analyses Analysis applied approach Asia candidate drug candidate drugs cisplatin co-expression Computational models contagious coronavirus Cyclophosphamide database disease drug Drug repurposing Drug screening drugs drugs targeting effective drug effective drugs FIVE FLUOROURACIL gene co-expression network Gene ontology Genes Genome Interaction list METHYLDOPA Microarrays miRNA miRNAs reconstructed respiratory Respiratory illness retrieved SARS-CoV SARS-CoV-2 SARS-CoV-2 coronavirus SARS-CoV-2 disease Severe acute respiratory syndrome Sirolimus Systems biology target gene the SARS-CoV-2 transcription factor transcription factors treat Treatment Viral viral respiratory virus [DOI] 10.1038/s41598-021-01410-3 PMC 바로가기 [Article Type] Article
ADEM post-Sars-CoV-2 infection in a pediatric patient with Fisher-Evans syndromeFisher-Evans 증후군이 있는 소아 환자의 Sars-CoV-2 감염 후 ADEMCase Reports Published on 2021-10-012022-09-11 Journal: Neurological Sciences [Category] SARS, 치료기술, [키워드] Acute disseminated encephalomyelitis ADEM age Asymptomatic Autoimmune disease available data characterized Clinical course Complication contributed Coronaviridae cortisone cortisone therapy described Disseminated encephalomyelitis Encephalomyelitis epilepsy episode episode of Evolution first positive Fisher-Evans Syndrome had no headache immunosuppressive immunosuppressive therapy Infection knowledge majority monosymptomatic MRI Nasopharyngeal swab neurological manifestation no symptoms Patient pediatric RNA virus SARS-COV-2 infection SARS-CoV2 infection Seizure Sirolimus Symptoms syndrome thalidomide therapy [DOI] 10.1007/s10072-021-05311-1 PMC 바로가기 [Article Type] Case Reports
Ex vivo SARS-CoV-2 infection of human lung reveals heterogeneous host defense and therapeutic responses인간 폐의 생체 외 SARS-CoV-2 감염은 이질적인 숙주 방어 및 치료 반응을 나타냅니다Research Article Published on 2021-09-222022-09-10 Journal: JCI Insight [Category] SARS, 치료기술, 치료제, [키워드] animal models antiviral activity Biology bridge Cell cell line cell lines cell viability Cellular immune response Chloroquine clinical risk factor Clinical risk factors comparable COVID-19 COVID-19 infection COVID-19 pathogenesis cryobank CXCL8 Defense demonstrated detectable Dexamethasone Donor donors Drug screening Drug screens endothelial epithelial Ex vivo expression had no HCoV HCoV-OC43 heterogeneity heterogeneous heterogenous Host host response human infection human lung human lung tissue human SARS-CoV-2 IFNB1 IL6 Immune cell Infection Inflammation library mechanism metformin molecules N-hydroxycytidine OC43 Pathogens Population predicted preserved Remdesivir respiratory Respiratory pathogens reveal Sample SARS-CoV-2 SARS-COV-2 infection severe COVID-19 Sirolimus subset suppressed susceptibility susceptibility to infection therapeutic response tissue tissues viability Viral viral growth viral replication [DOI] 10.1172/jci.insight.148003 PMC 바로가기 [Article Type] Research Article